Compare BSX & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BSX | NVO |
|---|---|---|
| Founded | 1979 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | 69500 |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.8B | 172.5B |
| IPO Year | 2010 | N/A |
| Metric | BSX | NVO |
|---|---|---|
| Price | $68.54 | $38.12 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 20 | 11 |
| Target Price | ★ $108.75 | $51.00 |
| AVG Volume (30 Days) | 11.6M | ★ 18.6M |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.17% |
| EPS Growth | ★ 55.20 | N/A |
| EPS | ★ 1.94 | N/A |
| Revenue | ★ $9,076,000,000.00 | N/A |
| Revenue This Year | $12.04 | N/A |
| Revenue Next Year | $10.48 | $3.30 |
| P/E Ratio | $35.87 | ★ $13.60 |
| Revenue Growth | ★ 12.49 | N/A |
| 52 Week Low | $68.25 | $35.85 |
| 52 Week High | $109.50 | $82.23 |
| Indicator | BSX | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 28.12 | 32.80 |
| Support Level | N/A | $35.85 |
| Resistance Level | $76.77 | $50.30 |
| Average True Range (ATR) | 1.86 | 0.90 |
| MACD | 0.04 | 0.31 |
| Stochastic Oscillator | 11.95 | 42.84 |
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.